Table 3.

HRQoL results as reported in randomized clinical trials assessing nail psoriasis-specific HRQoL

Reference	Instrument	Results
Elewski et al. 2018 [27]	NPQ10	Adalimumab (n = 109), mean values: baseline: 5.1; week 16: 0.4; week 26: 0.6 Placebo (n = 107), mean values: baseline: 5.4; week 16: 3.1; week 26: 3.3 Significant difference between adalimumab and placebo (p < 0.001)
Elewski et al. 2019 [28]	NPQ10	Adalimumab, continuing from blinded period (until week 26) to open-label period (n = 94), mean values: baseline: 4.9; week 26: improvement from baseline by 3.4 (as observed); week 52: improvement from baseline by 4.2 (as observed)
	NAPPA-QOL	Adalimumab, continuing from blinded period (until week 26) to open-label period (n = 94): baseline: 3.1; week 26: mean improvement from baseline by 1.3 (as observed); week 52: mean improvement from baseline by 1.6 (as observed)
Reich et al. 2019 [26]	NAPPA-QOL	Secukinumab 300 mg (n = 66): week 16: 59.3% median percentage improvement from baseline (no baseline values reported) Secukinumab 150 mg (n = 67): week 16: 44.5% median percentage improvement from baseline (no baseline values reported) Placebo (n = 65): week 16: 19% median percentage improvement from baseline (no baseline values reported) Significant difference between secukinumab 300 mg and secukinumab 150 mg, respectively, as compared to placebo (both p < 0.001)
	DLQI	Secukinumab 300 mg (n = 66): week 16: 62.9% DLQI 0/1 (no baseline values reported) Secukinumab 150 mg (n = 67): week 16: 44.6% DLQI 0/1 (no baseline values reported) Placebo (n = 65): week 16: 5.1% DLQI 0/1 (no baseline values reported) Significant difference between secukinumab 300 mg and secukinumab 150 mg, respectively, compared with placebo (both p < 0.001)
	EQ-5D	Secukinumab 300 mg (n = 66), health state as percentage of full health: baseline: 73%; week 16: 80% Secukinumab 150 mg (n = 67), health state as percentage of full health: baseline: 68%; week 16: 85% Placebo (n = 65), health state as percentage of full health: baseline: 69%; week 16: 60%
Reich et al. 2020 [9]	NAPPA-QOL	Secukinumab 300 mg (n = 66): at 2.5 years: 52.4% mean improvement from baseline (no baseline values reported) Secukinumab 150 mg (n = 67): at 2.5 years: 18.1% mean improvement from baseline (no baseline values reported)
	DLQI	Secukinumab 300 mg (n = 66): at 2.5 years: 53.8% DLQI 0/1 (no baseline values reported) Secukinumab 150 mg (n = 67): at 2.5 years: 45.5% DLQI 0/1 (no baseline values reported)
	EQ-5Da	Secukinumab 300 mg (n = 66), per domain, % reporting impairments, baseline vs. 2.5 years: mobility 27.7% vs. 9.2%; self-care 13.8% vs. 0.0%; usual activities 38.5% vs. 12.3%; pain/discomfort 76.9% vs. 29.2%; depression/anxiety 46.2% vs. 24.6% Secukinumab 150 mg (n = 67), per domain, % reporting impairments, baseline vs. 2.5 years: mobility 25.8% vs. 12.1%; self-care 18.2% vs. 7.6%; usual activities 36.4% vs. 12.1%; pain/discomfort 80.3% vs. 40.9%; depression/anxiety 57.6% vs. 25.8%

DLQI Dermatology Life Quality Index (range 0–30), DLQI 0/1 DLQI of 0 (indicating no effect at all on a patient's life), EQ-5D HRQoL questionnaire developed by the EuroQoL group, HRQoL health-related quality of life, NPQ10 Nail Psoriasis Quality of Life Scale (range 0–10), NAPPA-QOL Nail Assessment in Psoriasis and Psoriatic Arthritis–Quality of Life (range 0–4)

^aPer domain